Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The adverse side effects in a series of 439 myelographies with metrizamide were analyzed. The most frequent side effect was headache, which could be differentiated as early onset headache, related to hydrodynamic modifications in the spinal fluid following lumbar puncture, and late onset headache related to a metrizamide effect. The frequency of late onset headache was at least 27%, but all together 46% of the patients had postmyelographic headache. Meningeal irritation was seen in 5%, sometimes in a severe form, mimicking a septic complication. Spinal irritation and epileptic fits were rarely seen. Striking was the occurrence of an acute psycho-organic syndrome, frequently observed after cervical myelography which was performed with a higher than usual dose of iodine. We can not confirm the general opinion that the central nervous system had a good tolerance for metrizamide.
 ...
PMID:Adverse side effects of metrizamide in myelography. 49 14

A case of a girl (10 years old) with a psycho-organic syndrome plus headache without signs of clear intracranial hypertension is related. The diagnosis of neurocysticercosis was made by CSF abnormalities. PLEDs over the left cerebral hemisphere were recorded at the first day after treatment with praziquantel (50mg/kg/day during 21 days). The first CT scan was normal and just after the treatment showed a prominent left cerebral hemisphere involvement, despite parenchymatous dissemination of cysticerci was bilateral. The treatment was successful and the patient became asymptomatic in the two years follow-up. The neurophysiologic aspects of this EEG abnormality is also discussed.
 ...
PMID:[Periodic lateralized epileptiform discharges in neurocysticercosis]. 276 55

Iohexol, a new water-soluble nonionic contrast medium, was evaluated in clinical trials in Europe and North America for lumbar, thoracic, and cervical myelography using direct C1-2 or lumbar puncture. Iohexol was administered at 180, 240, or 300 mg I/ml to 677 adult patients for visualization of the lumbar subarachnoid space, and to 368 adult patients for evaluation of the cervical area. Compared with metrizamide, use of iohexol resulted in equivalent opacification but significantly reduced patient morbidity (headache, nausea, vomiting, dizziness). No epileptogenic activity was recorded in over 370 patients receiving iohexol. No mental or psycho-organic syndrome manifestations were observed in any of the 1,045 patients receiving iohexol. Adverse reactions occurring after iohexol injection were not related to the concentration or site used or to total dose administered. Iohexol has, thus far, proven superior to metrizamide for myelography.
 ...
PMID:Iohexol: summary of North American and European clinical trials in adult lumbar, thoracic, and cervical myelography with a new nonionic contrast medium. 388 16